MedTrace Logo

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

NCT06199882 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-10-15

No results posted yet for this study

Summary

This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent biliary tract cancer after the first surgery.

Conditions

  • Biliary Tract Carcinoma

Interventions

DRUG

SBRT Sequential Surufatinib Combined With Immunotherapy

1. SBRT : Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week). 2. Drug treatment (every 3 weeks is a treatment cycle) : 1\) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle.

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Luying Liu, M.D. · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06199882 on ClinicalTrials.gov